The prognostic impact of body mass index (BMI) in early breast cancer (BC) patients (pts)
Abstract
882 Background: High BMI has been associated with poor outcome in breast cancer patients Methods: We analyzed the impact of BMI on the survival outcome of 273 pre and postmenopausal BC pts who received adjuvant systemic therapy between 1998–2004 in our department. We also recorded the clinical, pathological and treatment characteristics and analyzed the relation of these parameters with BMI. Results: The median age was 51(23–85). The median follow up was 29 months (3–107).The median height, weight and BMI were 159cm (145–175), 66kg (39–117), 26,6 (17,7–54,5) respectively. The BMI was 30 (obese) in 27% pts. Fifty-five (n=146) % of pts were postmenopausal, 55% pts had stage 3, 29% pts had stage 2 disease. Pathologically, 58% pts had node positive disease, 88% had grade 2–3 tms, 86% had invasive ductal carcinoma, 74% had ER and/or PgR positive tms. Seventy-six (26%) pts had breast conserving surgery, 96% pts received adjuvant chemotherapy (CT) (5% received CMF and the others received anthracycline-based CT), 68% received adjuvant radiotherapy (RT). Among 186 pts with ER and/or PgR, one pt received anastrozole and the rest received tamoxifen after completion of CT and RT. In univariate analysis, a high BMI (overweight and/or obese) was more frequent in postmenopausal pts (p=0.00). In multivariate analysis none of the clinical, pathological factors, BMI, height and weight were found to have a significant impact on DFS and OS. The 5yr-DFS was 82% and OS was 90%. There was no…
Read the paper
Related studies
- A Coupled SYSTEM of Intracellular Ca 2+ Clocks and Surface Membrane Voltage Clocks Controls the Timekeeping Mechanism of the Heart’s Pacemaker
- A Comprehensive Review on the Therapeutic Potential of Curcuma longa Linn. in Relation to its Major Active Constituent Curcumin
- Cancer epigenetics: Moving forward
- Current developments in LC-MS for pharmaceutical analysis
- Myricetin: A comprehensive review on its biological potentials
- A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.